US5981485A
(en)
*
|
1997-07-14 |
1999-11-09 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
US5763394A
(en)
*
|
1988-04-15 |
1998-06-09 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
US5126324A
(en)
*
|
1990-06-07 |
1992-06-30 |
Genentech, Inc. |
Method of enhancing growth in patients using combination therapy
|
US5374620A
(en)
*
|
1990-06-07 |
1994-12-20 |
Genentech, Inc. |
Growth-promoting composition and its use
|
US5681814A
(en)
*
|
1990-06-07 |
1997-10-28 |
Genentech, Inc. |
Formulated IGF-I Composition
|
US5210017A
(en)
*
|
1990-11-19 |
1993-05-11 |
Genentech, Inc. |
Ligand-mediated immunofunctional hormone binding protein assay method
|
US6326154B1
(en)
*
|
1990-11-19 |
2001-12-04 |
Genentech, Inc. |
Ligand-mediated immunofunctional hormone binding protein assay method
|
DE4040954C2
(de)
|
1990-12-20 |
2001-05-17 |
Max Planck Gesellschaft |
Verfahren zur Erzeugung von pathogen-resistenten Pflanzen
|
SE9201073D0
(sv)
*
|
1992-04-03 |
1992-04-03 |
Kabi Pharmacia Ab |
Protein formulation
|
AU686567C
(en)
*
|
1992-07-31 |
2002-08-08 |
Genentech Inc. |
Human growth hormone aqueous formulation
|
US5643867A
(en)
*
|
1992-08-26 |
1997-07-01 |
Celtrix Pharmaceuticals, Inc. |
Method for treating catabolic conditions
|
US5444045A
(en)
*
|
1992-09-17 |
1995-08-22 |
Gropep, Pty. Ltd. |
Method of administering IGF-1, IGF-2, and analogs thereof to birds
|
US5273961A
(en)
*
|
1992-09-22 |
1993-12-28 |
Genentech, Inc. |
Method of prophylaxis of acute renal failure
|
JPH08502969A
(ja)
*
|
1992-10-29 |
1996-04-02 |
ジェネンテク,インコーポレイテッド |
肥満の予防または治療方法
|
SE9300105D0
(sv)
*
|
1993-01-15 |
1993-01-15 |
Kabi Pharmacia Ab |
Stable protein solution
|
SE9301667D0
(sv)
*
|
1993-05-14 |
1993-05-14 |
Kabi Pharmacia Ab |
New use
|
WO1995002411A1
(en)
*
|
1993-07-16 |
1995-01-26 |
Mallinckrodt Veterinary Limited |
Stabilised polypeptide growth factor formulation at low ph
|
US6046222A
(en)
*
|
1993-09-15 |
2000-04-04 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US20020049422A1
(en)
*
|
1994-03-31 |
2002-04-25 |
Brewitt Barbara A. |
Homeopathic preparations
|
US6239105B1
(en)
*
|
1994-03-31 |
2001-05-29 |
Barbara A. Brewitt |
Homeopathic preparations of purified growth hormone
|
US6207640B1
(en)
*
|
1994-04-07 |
2001-03-27 |
Genentech, Inc. |
Treatment of partial growth hormone insensitivity syndrome
|
US5646113A
(en)
*
|
1994-04-07 |
1997-07-08 |
Genentech, Inc. |
Treatment of partial growth hormone insensitivity syndrome
|
US5824642A
(en)
*
|
1994-04-07 |
1998-10-20 |
Genentech, Inc. |
Treatment of partial growth hormone insensitivity syndrome
|
US5610134A
(en)
*
|
1994-04-15 |
1997-03-11 |
Genentech, Inc. |
Treatment of congestive heart failure
|
US5661122A
(en)
*
|
1994-04-15 |
1997-08-26 |
Genentech, Inc. |
Treatment of congestive heart failure
|
US5444047A
(en)
*
|
1994-06-16 |
1995-08-22 |
Dipasquale; Gene |
Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
|
US5922673A
(en)
*
|
1994-09-21 |
1999-07-13 |
Chiron Corporation |
Method of treating hypertension in pregnant mammals
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
AU693478B2
(en)
*
|
1994-11-10 |
1998-07-02 |
Metabolic Pharmaceuticals Limited |
Treatment of obesity
|
US6335319B1
(en)
|
1994-11-15 |
2002-01-01 |
Metabolic Pharmaceuticals, Inc. |
Treatment of obesity
|
US20020142965A1
(en)
*
|
1994-11-15 |
2002-10-03 |
Metabolic Pharmaceuticals, Ltd. |
Treatment of obesity
|
WO1996019235A1
(en)
*
|
1994-12-21 |
1996-06-27 |
Auckland Uniservices Limited |
Enhancement of fetal growth by administration of insulin-like growth factor-1(igf-1)
|
KR19980701351A
(ko)
*
|
1995-01-13 |
1998-05-15 |
슈타르 피아 |
성장호르몬 및 X-Lys를 함유하는 안정화된 약제조제물(A STABILIZED PHARMACEUTICAL FORMULATION COMPRISING A GROWTH HORMONE AND X-Lys
|
ZA96122B
(en)
*
|
1995-01-13 |
1996-07-24 |
Novo Nordisk As |
A pharmaceutical formulation
|
US5705482A
(en)
*
|
1995-01-13 |
1998-01-06 |
Novo Nordisk A/S |
Pharmaceutical formulation
|
SE9501472D0
(sv)
*
|
1995-04-21 |
1995-04-21 |
Pharmacia Ab |
Truncated IGF-I
|
US5741776A
(en)
*
|
1995-05-22 |
1998-04-21 |
Genentech, Inc. |
Method of administration of IGF-I
|
US5565428A
(en)
*
|
1995-05-22 |
1996-10-15 |
Genentech, Inc. |
Method of administration of IGF-I
|
PT828758E
(pt)
*
|
1995-05-26 |
2002-02-28 |
Theratechnologies Inc |
Analogos quimericos de corpo gordo-pro-grf com potencia biologica aumentada
|
EP0766966A3
(en)
*
|
1995-09-08 |
2001-02-28 |
Eli Lilly And Company |
Method of treating insulin resistance
|
DE69628909T2
(de)
|
1995-10-12 |
2003-12-24 |
Supergen Inc |
Liposomformulierung von 5-beta steroiden
|
AUPN801296A0
(en)
*
|
1996-02-12 |
1996-03-07 |
Csl Limited |
Stabilised growth hormone formulation and method of preparation thereof
|
US5948757A
(en)
*
|
1996-03-01 |
1999-09-07 |
Celtrix Pharmaceuticals, Inc. |
High dose IGF-1 therapy
|
AU2334097A
(en)
*
|
1996-03-21 |
1997-10-10 |
Merck & Co., Inc. |
4-spiroindoline piperidines promote release of growth hormone
|
US20070179096A1
(en)
*
|
1996-04-24 |
2007-08-02 |
Novo Nordisk A/S |
Pharmaceutical Formulation
|
US5783556A
(en)
*
|
1996-08-13 |
1998-07-21 |
Genentech, Inc. |
Formulated insulin-containing composition
|
JP4695735B2
(ja)
*
|
1996-08-26 |
2011-06-08 |
シグナル ファーマシューティカルズ, エルエルシー |
刺激誘導性I(κ)Bキナーゼ[IKK]シグナルソーム
|
US5855920A
(en)
*
|
1996-12-13 |
1999-01-05 |
Chein; Edmund Y. M. |
Total hormone replacement therapy
|
ZA9711731B
(en)
*
|
1996-12-31 |
1998-07-01 |
Monsanto Co |
Aqueous glycerol formulations of somatotropin
|
FR2758460B1
(fr)
*
|
1997-01-21 |
1999-12-31 |
Sanofi Sa |
Utilisation des agonistes des recepteurs beta-3 adrenergiques pour la preparation de medicaments cicatrisants
|
US6004932A
(en)
*
|
1997-03-06 |
1999-12-21 |
Iowa State University Research Foundation, Inc. |
Use of glucagon as a metabolic conditioner for dairy cows and other ruminants
|
US6121416A
(en)
|
1997-04-04 |
2000-09-19 |
Genentech, Inc. |
Insulin-like growth factor agonist molecules
|
US6420518B1
(en)
|
1997-04-04 |
2002-07-16 |
Genetech, Inc. |
Insulin-like growth factor agonist molecules
|
US5866546A
(en)
*
|
1997-04-18 |
1999-02-02 |
Hadasit Medical Research Services And Development Company Ltd. |
Treatment for diabetes
|
US5840042A
(en)
*
|
1997-05-16 |
1998-11-24 |
St. Luke's-Roosevelt Hospital |
Method of predicting body composition in prepubertal children infected with human immunodenficiency virus
|
WO1999012969A1
(en)
*
|
1997-09-08 |
1999-03-18 |
Metabolic Pharmaceuticals Ltd. |
Treatment of obesity
|
EP1028746B1
(en)
|
1997-11-07 |
2003-02-26 |
Chiron Corporation |
Method for producing igf-i sustained-release formulations
|
US6767892B1
(en)
*
|
1997-11-07 |
2004-07-27 |
Chrion Corporation |
Compositions providing for increased IGF-I solubility
|
SE9704405D0
(sv)
*
|
1997-11-28 |
1997-11-28 |
Pharmacia & Upjohn Ab |
New syringe
|
PT1069912E
(pt)
*
|
1998-04-03 |
2007-09-14 |
Novartis Vaccines & Diagnostic |
Formulações injectáveis de igf contendo succinato como agente tampão
|
US6013622A
(en)
*
|
1998-04-15 |
2000-01-11 |
Nutriceutical Technology Corporation |
Method of regulating appetite and metabolism
|
ATE499445T1
(de)
*
|
1998-12-10 |
2011-03-15 |
Signal Pharm Llc |
Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
|
US6696063B1
(en)
*
|
1998-12-30 |
2004-02-24 |
Applied Research Systems Ars Holding N.V. |
Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
|
PT1141014E
(pt)
*
|
1999-01-06 |
2005-04-29 |
Genentech Inc |
Variante mutante do factor de crescimento semelhante a insulina (igf-i)
|
EP1165119B1
(en)
|
1999-04-08 |
2003-10-08 |
Genentech, Inc. |
Composition based on oppositely-charged polypeptides
|
MXPA02000404A
(es)
*
|
1999-07-12 |
2004-05-21 |
Grandis Biotech Gmbh |
Formulaciones de hormona de crecimiento.
|
US6521266B1
(en)
*
|
1999-09-23 |
2003-02-18 |
Morris A. Mann |
Composition for growth hormone production and release, appetite suppression, and methods related thereto
|
JP2003534237A
(ja)
*
|
1999-11-03 |
2003-11-18 |
ノボ ノルディスク アクティーゼルスカブ |
食欲の抑制又は満腹の惹起のための成長ホルモン又は成長ホルモン分泌促進物質の使用
|
AU2001233144A1
(en)
*
|
2000-01-31 |
2001-08-07 |
The University Of Kentucky Research Foundation |
Triazines as appetite suppressor
|
EP1282437B1
(en)
|
2000-05-16 |
2008-03-19 |
Genentech, Inc. |
Treatment of cartilage disorders
|
CA2380423A1
(en)
*
|
2000-05-17 |
2001-11-22 |
Bionebraska, Inc. |
Peptide pharmaceutical formulations
|
DE10035227A1
(de)
*
|
2000-07-20 |
2002-01-31 |
Solvay Pharm Gmbh |
Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
|
US6946243B2
(en)
*
|
2000-07-20 |
2005-09-20 |
Solvay Pharmaceuticals Gmbh |
Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
|
US20060159724A1
(en)
*
|
2000-08-08 |
2006-07-20 |
Bell Stacey J |
Nutritional supplement for the management of weight
|
US7493171B1
(en)
|
2000-11-21 |
2009-02-17 |
Boston Scientific Neuromodulation Corp. |
Treatment of pathologic craving and aversion syndromes and eating disorders by electrical brain stimulation and/or drug infusion
|
US6832114B1
(en)
|
2000-11-21 |
2004-12-14 |
Advanced Bionics Corporation |
Systems and methods for modulation of pancreatic endocrine secretion and treatment of diabetes
|
US7440806B1
(en)
|
2000-11-21 |
2008-10-21 |
Boston Scientific Neuromodulation Corp. |
Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion
|
US6950707B2
(en)
|
2000-11-21 |
2005-09-27 |
Advanced Bionics Corporation |
Systems and methods for treatment of obesity and eating disorders by electrical brain stimulation and/or drug infusion
|
US6922590B1
(en)
|
2000-11-21 |
2005-07-26 |
Advanced Bionics Corporation |
Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion
|
CA2431517A1
(en)
|
2000-12-12 |
2002-08-01 |
University Of Connecticut |
Polynucleotides encoding cellular transporters and methods of use thereof
|
US20030082647A1
(en)
*
|
2000-12-12 |
2003-05-01 |
Reenan Robert A. |
Transporter protein
|
EP1390060A2
(en)
*
|
2001-01-26 |
2004-02-25 |
Eli Lilly And Company |
Use of lp82 to treat body weight disorders
|
ATE439378T1
(de)
*
|
2001-02-09 |
2009-08-15 |
Genentech Inc |
Verfahren zur identifizierung von indirekten igf- 1-agonisten
|
US7060675B2
(en)
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
GB0112363D0
(en)
|
2001-05-21 |
2001-07-11 |
Allied Therapeutics Ltd |
Method and apparatus for treating biological fluids
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6713452B2
(en)
*
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828297B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
*
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6835802B2
(en)
*
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US20030072761A1
(en)
*
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
US20040162237A1
(en)
*
|
2002-01-15 |
2004-08-19 |
Fox Niles Wayne |
Use of lp82 to treat body weight disorders
|
NZ534757A
(en)
*
|
2002-03-12 |
2006-07-28 |
Merck & Co Inc |
Substituted amides
|
WO2003105768A2
(en)
|
2002-06-13 |
2003-12-24 |
Nobex Corporation |
Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
|
US20040122033A1
(en)
*
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
US8519008B2
(en)
|
2003-01-22 |
2013-08-27 |
Purina Animal Nutrition Llc |
Method and composition for improving the health of young monogastric mammals
|
EP1670413A4
(en)
*
|
2003-08-21 |
2009-07-08 |
Tercica Inc |
PROCESS FOR REDUCING VISCERAL FAT BY INCREASING THE MIRRORS OF THE INSULINARY GROWTH FACTOR (IGF-I)
|
CA2538342C
(en)
*
|
2003-09-12 |
2013-01-08 |
Tercica, Inc. |
Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
|
US8147561B2
(en)
|
2004-02-26 |
2012-04-03 |
Endosphere, Inc. |
Methods and devices to curb appetite and/or reduce food intake
|
US8585771B2
(en)
|
2004-02-26 |
2013-11-19 |
Endosphere, Inc. |
Methods and devices to curb appetite and/or to reduce food intake
|
US7931693B2
(en)
*
|
2004-02-26 |
2011-04-26 |
Endosphere, Inc. |
Method and apparatus for reducing obesity
|
EP1591114A1
(en)
*
|
2004-03-12 |
2005-11-02 |
Fournier Laboratories Ireland Limited |
Use of metformin and orlistat for the treatment or prevention of obesity
|
CN101027318B
(zh)
|
2004-07-19 |
2016-05-25 |
比奥孔有限公司 |
胰岛素-低聚物共轭物,制剂及其用途
|
CN101022820A
(zh)
*
|
2004-08-30 |
2007-08-22 |
特西卡股份有限公司 |
诊断和治疗胰岛素样生长因子缺陷疾病的方法和装置
|
WO2006130769A2
(en)
|
2005-06-02 |
2006-12-07 |
Tercica, Inc. |
Methods for treatment of growth disorders
|
US9458444B2
(en)
|
2006-02-03 |
2016-10-04 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US7553941B2
(en)
|
2006-02-03 |
2009-06-30 |
Modigene Inc |
Long-acting polypeptides and methods of producing same
|
US10351615B2
(en)
|
2006-02-03 |
2019-07-16 |
Opko Biologics Ltd. |
Methods of treatment with long-acting growth hormone
|
US9249407B2
(en)
|
2006-02-03 |
2016-02-02 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US8048849B2
(en)
|
2006-02-03 |
2011-11-01 |
Modigene, Inc. |
Long-acting polypeptides and methods of producing same
|
US20150038413A1
(en)
|
2006-02-03 |
2015-02-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US8450269B2
(en)
*
|
2006-02-03 |
2013-05-28 |
Prolor Biotech Ltd. |
Long-acting growth hormone and methods of producing same
|
US8946155B2
(en)
|
2006-02-03 |
2015-02-03 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US8476234B2
(en)
*
|
2006-02-03 |
2013-07-02 |
Prolor Biotech Inc. |
Long-acting coagulation factors and methods of producing same
|
US20140113860A1
(en)
|
2006-02-03 |
2014-04-24 |
Prolor Biotech Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US8759292B2
(en)
|
2006-02-03 |
2014-06-24 |
Prolor Biotech, Llc |
Long-acting coagulation factors and methods of producing same
|
US10221228B2
(en)
|
2006-02-03 |
2019-03-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US9060835B2
(en)
*
|
2006-05-26 |
2015-06-23 |
Endosphere, Inc. |
Conformationally-stabilized intraluminal device for medical applications
|
US8748419B2
(en)
*
|
2006-06-16 |
2014-06-10 |
Theracos, Inc. |
Treating obesity with muscarinic receptor M1 antagonists
|
US20080220104A1
(en)
*
|
2007-03-08 |
2008-09-11 |
Cappello John V |
Compositions for producing satiety
|
US20110137227A1
(en)
|
2007-07-16 |
2011-06-09 |
Mckinley James T |
Methods and devices for delivering or delaying lipids within a duodenum
|
WO2009050738A2
(en)
*
|
2007-10-16 |
2009-04-23 |
Biocon Limited |
An orally administerable solid pharmaceutical composition and a process thereof
|
US8986253B2
(en)
|
2008-01-25 |
2015-03-24 |
Tandem Diabetes Care, Inc. |
Two chamber pumps and related methods
|
US8408421B2
(en)
|
2008-09-16 |
2013-04-02 |
Tandem Diabetes Care, Inc. |
Flow regulating stopcocks and related methods
|
EP2334234A4
(en)
|
2008-09-19 |
2013-03-20 |
Tandem Diabetes Care Inc |
DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD
|
US9663778B2
(en)
|
2009-07-09 |
2017-05-30 |
OPKO Biologies Ltd. |
Long-acting coagulation factors and methods of producing same
|
US8758323B2
(en)
|
2009-07-30 |
2014-06-24 |
Tandem Diabetes Care, Inc. |
Infusion pump system with disposable cartridge having pressure venting and pressure feedback
|
KR101614983B1
(ko)
|
2009-11-17 |
2016-04-22 |
입센 파마 에스.에이.에스 |
Hgh 및 rhigf―1의 조합물을 위한 제제
|
US20110152188A1
(en)
*
|
2009-12-23 |
2011-06-23 |
Hanns-Christian Mahler |
Pharmaceutical compositions of igf/i proteins
|
JP2015520128A
(ja)
|
2012-04-19 |
2015-07-16 |
オプコ バイオロジクス リミテッド |
長時間作用性オキシントモジュリン変異体とその作製方法
|
US9180242B2
(en)
|
2012-05-17 |
2015-11-10 |
Tandem Diabetes Care, Inc. |
Methods and devices for multiple fluid transfer
|
KR102202255B1
(ko)
|
2012-11-20 |
2021-01-13 |
옵코 바이오로직스 리미티드 |
생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법
|
US9173998B2
(en)
|
2013-03-14 |
2015-11-03 |
Tandem Diabetes Care, Inc. |
System and method for detecting occlusions in an infusion pump
|
US20150158926A1
(en)
|
2013-10-21 |
2015-06-11 |
Opko Biologics, Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US10960058B2
(en)
|
2015-06-19 |
2021-03-30 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
CN118085104A
(zh)
|
2016-07-11 |
2024-05-28 |
Opko生物科学有限公司 |
长效凝血因子及其制备方法
|
KR102245539B1
(ko)
|
2018-02-12 |
2021-04-29 |
주식회사 지앤피바이오사이언스 |
코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
|
EP3811962A4
(en)
*
|
2018-06-25 |
2022-03-16 |
JCR Pharmaceuticals Co., Ltd. |
PROTEIN AQUEOUS LIQUID FORMULATION
|